Lupus autoimmunity altered by cellular methylation metabolism

Area of Science:

• Immunology
• Biochemistry
• Molecular Biology

Background:

• Methylation of DNA and proteins is crucial for immune responses and autoimmune diseases.
• Aberrant methylation, like in CpG dinucleotides and methylated proteins (e.g., SmD1/SmD3 in SLE), drives autoimmunity.
• S-adenosylmethionine (SAM) is the primary methyl donor in transmethylation reactions.

Purpose of the Study:

• To investigate the role of SAM metabolism in T cell immunity and autoimmune conditions.
• To evaluate the therapeutic potential of 5 '-deoxy-5 '-methylthioadenosine (MTA), a SAM metabolite, in suppressing T cell responses and autoimmune disease.
• To explore the impact of SAM and MTA on lymphocyte proliferation and autoimmune syndrome development.

Main Methods:

• Administered MTA to lupus-prone MRL/lpr mice.
• Assessed T cell activation markers, Th1/Th2 cytokines, and TCR signaling.
• Measured splenomegaly, lymphadenopathy, autoantibody titers, and kidney pathology.
• Incubated cells with SAM to increase intracellular MTA levels and assessed lymphocyte proliferation.

Main Results:

• MTA significantly inhibited T cell responses, including activation markers, cytokines, and TCR signaling.
• MTA treatment markedly reduced lupus symptoms in MRL/lpr mice, including organomegaly, autoantibodies, and kidney damage.
• SAM incubation, leading to increased MTA, dose-dependently inhibited T cell and B cell proliferation.

Conclusions:

• Altering SAM metabolism, specifically through MTA, effectively suppresses T cell immunity.
• MTA demonstrates significant therapeutic potential for T cell-mediated autoimmune diseases like lupus.
• These findings highlight MTA and SAM as key regulators of lymphocyte transmethylation and autoimmune responses.